Clinical trials: Large B-Cell Lymphoma (LBCL)
Large-cell Lymphoma
CAR-T ceLL for Eradication of Active Residual Disease in LBCL (CLEAR-1 Study)
This is a phase 1b clinical trial to assess the efficacy of rapcabtagene autoleucel (YTB323) administered at the recommended dose in adults with Large B Cell Lymphoma (LBCL) who are at high risk of relapse at end of first line…
- Trial name
- NCT07443137
- Testing
- Rapcabtagene autoleucel (YTB323)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Large B-Cell Lymphoma (LBCL)
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
CAR-T cell therapy targeting CD19 has been shown to be effective in heavily-pretreated B-cell ALL or NHL, but relapses post-CAR-T are common, and CD19 antigen loss is one of the reasons.
- Trial name
- NCT07461831
- Testing
- CD19/CD22 bispecific CAR-T cells
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Tongren Hospital
Large B-Cell Lymphoma (LBCL)
Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
This study is an open-label, single-arm, prospective, exploratory clinical trial involving patients with relapsed/refractory large B-cell lymphoma, aiming to preliminarily assess the safety and efficacy of CAR-T cell infusion.
- Trial name
- NCT07447726
- Testing
- CD19X CAR-T
- Volunteers
- 3 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Diffuse Large B-cell Lymphoma
Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients
In the current protocol version, there are two parts. Part I is a pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in…
- Trial name
- DALY 2-EU (NCT04844866)
- Testing
- MB-CART2019.1, Standard of Care
- Where
- 51 sites in Austria, Belgium and 12 more
- Volunteers
- 213 people
- Sponsor
- Miltenyi Biomedicine GmbH
Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma.
- Trial name
- EpcoReal (NCT06830759)
- Where
- 73 sites in Argentina, Australia and 11 more
- Volunteers
- 700 people
- Sponsor
- AbbVie
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
A Phase 2 Study of Firi-cel in Patients With Relapsed/Refractory Large B-cell Lymphoma
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a…
- Trial name
- FIRCE-1 (NCT05972720)
- Testing
- Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
- Where
- 31 sites in United States
- Volunteers
- 101 people
- Sponsor
- CARGO Therapeutics
Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or follicular lymphoma after a lymphodepletion regimen…
- Trial name
- ALPHA (NCT03939026)
- Testing
- ALLO-501, ALLO-647, Fludarabine
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Allogene Therapeutics
B-cell Lymphoma
Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.
Bendamustine and the combination of fludarabine/cyclophosphamide are fully authorized chemotherapy agents in Switzerland for lymphoma treatment and currently used in routine clinical practice as lymphodepletion strategy before…
- Trial name
- FC-BALANCE (NCT07593482)
- Testing
- bendamustine hydrochloride, Cyclophosphamide, Fludarabine
- Where
- 9 sites in Switzerland
- Volunteers
- 92 people
- Sponsor
- Swiss Cancer Institute
Large B-cell Lymphoma
Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
This is a Phase I/II study. The Phase I part will evaluate the safety and tolerability of sonrotoclax in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP), using a…
- Trial name
- NCT07638787
- Testing
- Polatuzumab Vedotin, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Ruijin Hospital
Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Nektar Study 18-255-01 was a Phase 2/3, randomized, double blind, placebo-controlled, multicenter study of NKTR-255 versus placebo following CD19-directed CAR-T cell therapy in patients with R/R LBCL.
- Trial name
- NCT05664217
- Testing
- NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg
- Where
- 7 sites in United States
- Volunteers
- 15 people
- Sponsor
- Nektar Therapeutics
Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL
This is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as…
- Trial name
- NCT06104592
- Testing
- Comprehensive Ablative Bridging Irradiation (CABI), Chimeric Antigen Receptor T-Cell Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
- Trial name
- NCT06149169
- Testing
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Large B-Cell Lymphoma (LBCL)
Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
Chimeric antigen receptor (CAR) T-cell therapy has been the standard of care for relapsed/refractory large B-cell lymphomas (R/R LBCLs) since 2018.
- Trial name
- NCT07524816
- Testing
- CAR-T cell therapy
- Where
- Belarus
- Volunteers
- 76 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Large B-cell Lymphoma, Lymphoma
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
To learn if loncastuximab tesirine (called "lonca" in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy.
- Trial name
- NCT05464719
- Testing
- Loncastuximab Tesirine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Large B-Cell Lymphoma (LBCL)
AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
This is a prospective, open-label, multicenter, randomized controlled study in older treatment-naive patients with LBCL. Participants will be stratified into different risk groups using an AI-based multimodal model.
- Trial name
- PRAISE (NCT07717177)
- Testing
- Polatuzumab Vedotin, Rituximab (R), Zanubrutinib
- Where
- China
- Volunteers
- 112 people
- Sponsor
- Ruijin Hospital
Non-Hodgkin's Lymphoma
Ph II CHOP+Velcade in Mediastinal LBCL
The main purpose of this study is to begin to collect information and try to learn whether or not VELCADE, when added to standard chemotherapy with CHOP/Rituxan, works in treating patients mediastinal large B-cell lymphoma.
- Trial name
- NCT00361621
- Testing
- bortezomib, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma
This phase I/II trial tests the safety, side effects, and best dose/regimen of ST-067 in combination with CD19-directed chimeric antigen receptor (CAR) T-cell therapy (liso-cel) and how well it works in treating patients with…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High-Grade B-Cell Lymphoma
- Trial name
- NCT07098364
- Testing
- Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Fred Hutchinson Cancer Center
Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
This study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
- Trial name
- NCT07613788
- Testing
- Rimegepant, Glofitamab, Obinutuzumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Large B-Cell Lymphoma (LBCL)
CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
A Study of CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma
- Trial name
- NCT04661020
- Testing
- CD19 CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang University
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
This is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323).
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia
- Trial name
- NCT03960840
- Testing
- Rapcabtagene autoleucel single agent, Ibrutinib
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 218 people
- Sponsor
- Novartis Pharmaceuticals